![]() |
|
|
Food and Nutritional Science Program, Department of Zoology, The University of Hong Kong, Hong Kong, The Peoples Republic of China
2To whom correspondence should be addressed. E-mail: etsli{at}hkucc.hku.hk.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: bitter melon glucose tolerance free fatty acids visceral fat hyperinsulinemia rats
An increase in the prevalence of type 2 diabetes has been reported worldwide (1
). Although hypoglycemic agents, dietary fiber and low glycemic index foods are widely available, the public continues to maintain a substantial interest in dietary adjuncts that possess hypoglycemic properties. Over 1000 herbal products have been used by various cultures to lower blood glucose and treat diabetes. Among them, Momordica charantia (family Cucurbitaceae, commonly known as ku gua, karela, bitttergourd or bitter melon) is the most popular herbal resource (2
). Documentation on the pharmacologic properties of bitter melon (BM) dates back to the 16th century (3
). The hypoglycemic potential of BM has been demonstrated in normal and diabetic rats (4
7
) and in patients with type 2 diabetes (5
,8
). Although BM has been shown to inhibit glucose absorption (9
), promote hepatic glucose utilization (6
), possess an insulin-like polypeptide (10
) and even to increase insulin-positive cell number in the pancreas (11
), the mechanism(s) whereby BM lowers blood glucose remain uncertain. Emerging evidence also suggests a hypolipidemic action of BM. BM supplementation lowered serum cholesterol, hepatic total cholesterol and triglyceride in normal rats (12
14
) and elevated HDL cholesterol in streptozotocin-induced diabetic rats (14
). With the compelling evidence that BM affects glucose and lipid metabolism, the lack of information in the literature on the effect of BM in rats fed a hyperinsulinemic high fat (HF) diet is surprising. The present study was carried out to test our hypothesis that BM-induced substrate and hormonal changes are associated with a reduction in adiposity. The first experiment examined the dose-dependent effects of freeze-dried BM juice on female rats fed a HF diet. On the basis of improvements in oral glucose tolerance, 0.75%BM was selected for use in the next experiment. The objective of the second experiment was to determine energy efficiency and adiposity of male rats when their habitual HF diet was replaced by a HF+BM, low fat (LF) or LF+BM diet. Potential mechanisms were explored by monitoring apparent fat absorption, serum free fatty acids (FFA), insulin, leptin and tumor necrosis factor-
(TNF-
).
| MATERIALS AND METHODS |
|---|
|
|
|---|
Unripe BM fresh fruit purchased from a local market was washed thoroughly with water, cut open and the seeds removed. An electric juicer (Braun MP 80, Kronberg, Germany) was used to extract the juice from the edible portion. The juice (
500 mL/kg) was frozen and then completely lyophilized by continuous freeze-drying operation for 72 h (Dura Bulk Tray Dryer, FTS System, Stone Ridge, NY). The yield was
16 g powder/kg fresh fruit. The BM powder was kept in airtight containers at -70°C until used.
Experimental diet.
The formulation of the powder diets (Table 1 ) was based on the AIN-93G recommendation (15 ). The LF diet contained 7 g fat/100 g diet. The HF diet (30 g fat/100 g diet) was obtained by adding Crisco shortening (Procter & Gamble, Cincinnati, OH), containing mainly partially hydrogenated soybean and cottonseed oils, mono- and diglycerides, at the expense of cornstarch. The freeze-dried bitter melon juice powder was also added at the expense of cornstarch.
|
All animal protocols were approved by the committee on the use of live animals in teaching and research, The University of Hong Kong. Rats, at 6 wk of age, were obtained from the existing colony in the animal unit of the Medicine Faculty. They were housed individually in rectangular hanging wire cages in an environmentally controlled room (12-h cycle with lights on at 0700 h; 22 ± 2°C). Rats were given free access to water and consumed laboratory food (Lab Diet-The Richmond Standard, PMI Nutrition International, St Louis, MO) until they were assigned to individual groups.
Experiment 1.
Female Sprague-Dawley rats were fed a LF or HF diet for 6 wk. At the beginning of wk 7, the LF-fed rats either continued to consume the same diet (LF, n = 5) or were switched to a LF diet containing 1.5% BM (LF + 1.5%BM, n = 4). Some of the HF rats continued to consume the HF diet (HF, n = 8), whereas others were switched to one of the following diets: HF + 0.375%BM (n = 9), HF + 0.75%BM (n = 9), and HF + 1.5%BM (n = 8). Rats were weighed twice weekly. Feed intake was monitored daily. At the end of wk 15, rats that had been food-deprived for 8 h were killed by decapitation between 1600 and 1800 h. Blood was collected from the cervical wound into chilled test tubes. Blood was centrifuged (2,000 x g at 4°C) and the serum stored at -70°C until used. Liver and visceral (intra-abdominal) fat, including mesenteric, perirenal, perigonadal and retroperitoneal depots, were excised, weighed and stored at -70°C.
Experiment 2.
Male Sprague-Dawley rats were fed a LF (n = 7) or HF (n = 32) diet. Beginning at wk 5, the HF-fed rats were randomly assigned to one of the four diets (Table 1) : HF, HF containing 0.75% BM (HF/HF+BM), LF (HF/LF) and LH containing 0.75% BM (HF/LF+BM). At the end of wk 11, the rats were killed; blood and tissues were collected as in the previous experiment. Plasma glucose and serum FFA were determined immediately.
Oral glucose tolerance test (OGTT).
The test was conducted on rats after 5 wk of BM supplementation, i.e., in the afternoon of wk 12 and 10 for Experiment 1 and 2, respectively. On test days, rats were deprived of food for 8 h; then a blood sample from the capillary bed of the tail tip was collected in microvette coated with fluoride and heparin (Sarstedt, Germany). Rats then administered a 200 g/L glucose solution by gavage (7.5 mL/kg). Tail blood was collected 30, 60 and 90 min after the gavage.
Apparent fat absorption.
In Experiment 2, feces of rats were collected on three consecutive days (d 4648). The fecal samples were stored at -70°C for the determination of fat content.
Measurements.
Plasma glucose was assayed immediately using a commercially available glucose oxidase kit (kit No. 510-A, Sigma Chemical, St. Louis, MO). Serum FFA concentration was determined by an enzymatic colorimetric assay (NEFA C test kit, Wako, Osaka, Japan). ELISA kits were used to measure serum leptin (Active Murine leptin DSL-1024100, Diagnostic Systems Laboratories, Webster, TX), insulin (Mercodia rat insulin 101124-01, Mecordia AB, Uppsala, Sweden) and TNF-
(Rat TNF
Ultra Sensitive KRC 3014, BioSource International, Camarillo, CA). The total fat content in feces and diets was determined gravimetrically. The samples were dried (105°C for 12 h) and then extracted with petroleum ether under reflux (16
). On the basis of the 3-d intake and excretion data, apparent fat absorption was calculated using the formula: [(fat intake fecal fat)/fat intake] x 100.
Statistical methods.
Data are expressed as mean ± SEM. Analyses were carried out with the Statistical Package for the Social Science (SPSS for Windows, version 10.1, Chicago, IL). To determine treatment effect and compare differences among group means, data were analyzed by one-way ANOVA followed by post-hoc Duncans multiple range test. Correlation analysis was performed to determine the relationship between two variables. Statistical significance was accepted at P < 0.05.
An insulin resistance index (IRI) was calculated as the product of insulin and glucose concentration (10-3 pmol insulin x mmol glucose/L2) for each individual rat (17 ,18 ). Area under the curve for glucose (AUCglucose) was determined using the trapezoidal rule.
| RESULTS |
|---|
|
|
|---|
In Experiment 1, the 9-wk weight gain of the HF group was 217% that of the LF group (Table 2 ). Although weight gain of the HF + 1.5%BM group was only 54% that of the HF group, large within-group variability rendered the dose-response effect nonsignificant (P = 0.075). With the addition of BM, energy efficiency (EE) progressively decreased. Energy efficiency of the HF + 1.5%BM group was significantly lower than that of the HF group (P < 0.05).
|
|
Visceral fat mass of the HF group was higher than that of the LF group (P < 0.05). There was a trend (P = 0.10) for a decrease in visceral fat mass when female rats were supplemented with BM (Table 4 ). Fat mass in these rats also correlated with body weight gain (r = 0.930, df = 41, P < 0.01).
|
|
The addition of BM to the HF diet improved oral glucose tolerance (Fig. 1 ). The AUCglucose of the HF + 0.75%BM and HF + 1.5%BM groups were lower than that of the HF group (P < 0.05).
|
|
and FFA.In Experiment 1, serum insulin and leptin correlated strongly with visceral fat mass (r = 0.843 and 0.743, df = 32, P < 0.001) among the HF-fed rats. There was a trend (P = 0.059) for IRI to decrease with the addition of BM (Table 4) .
In Experiment 2, IRI was significantly lower for the LF, HF/LF, HF/LF+BM and HF/HF+BM rats compared with the HF rats (P < 0.005, Table 5
). Male rats switched from the HF to the LF, LF+BM or HF+BM diet had significantly lower serum leptin concentration (P < 0.05). In this experiment, serum TNF-
concentrations did not differ among groups. Its concentration did not correlate with visceral fat mass (r = -0.28, df = 37, P = 0.088). Interestingly, serum FFA concentration was significantly elevated when rats switched from a HF diet to a LF, LF+BM or HF+BM diet (P < 0.05, Table 5
).
| DISCUSSION |
|---|
|
|
|---|
Bitter melon (BM) is a widely cultivated plant for food and medicinal uses. The medicinal properties of its fruit, seeds, vines and leaves are recorded in Ben Cao Gang Mu, an ancient Chinese pharmacopoeia (3
). In folklore medicine, BM juice is used as a herbal remedy for a variety of aliments including colic, gout and diabetes (19
). Among the documented effects of BM (20
,21
), its hypoglycemic effect perhaps has received the most attention. Results of the present study indicate an improvement in insulin resistance in rats fed the HF diet and also provide new evidence for a role of BM in body weight management. Because glycemic control is related in part to weight (fatness) (22
), the high fat feeding regimen allowed us to examine these two variables during consumption of BM. In the dose-response study, female rats were used (Experiment 1). The rationale was that if BM affects body weight, the effect might be better demonstrated in slow-growing adult females. Although body weight statistics were hampered by the larger than anticipated variability, a dose-dependent decrease in EE that was significant at the highest dose of BM was noted (Table 2)
. Because the oral glucose tolerance of rats fed the HF diet was improved when BM was added at a dose
0.75% (Fig. 1)
, the effects of 0.75%BM were tested again in male Sprague-Dawley rats, which in our experience, have more consistent responses to a HF diet. In Experiment 2, BM clearly reduced adiposity (Table 3)
and improved insulin resistance (Table 5)
of the rats fed the HF diet.
The deceleration in body weight gain in BM-supplemented rats was associated with lower EE. Because neither energy intake nor absorption efficiency was altered, less efficient metabolic processes are implicated in the HF+BM rats. In Experiment 2, a LF or a LF+BM diet replaced the habitual HF diet in two groups of rats. This design was used to further examine the effect of BM on rats during deceleration in weight gain. The result was somewhat unexpected. Weight gain (and fat deposition) of the HF/LF+BM group was not different from that of the HF/LF group (Tables 3 and 5) . Therefore, BM appeared to have lost its effect in rats that were already engaged in a metabolic process leading to a lower EE. Whether a higher dose would make a difference awaits testing.
The mechanisms whereby BM lowers EE and reduces visceral fat mass accumulation remain unknown. Changes in substrate and hormone concentrations, however, suggest that the low insulin environment that accompanied BM supplementation might favor lipolysis. Indeed, serum FFA concentration was increased in rats fed the BM-supplemented HF diet (Table 5) . Others have reported lower triglyceride levels in plasma (14 ) and liver (13 ,14 ) in BM-treated rats. Taken together, these data suggest that BM may suppress lipogenesis (LF group) or lipid deposition (HF group) but favor fat mobilization. The FFA might become substrates for the uncoupling proteinmediated adaptive thermogenesis that is important to the maintenance of energy balance in rodents (23 ,24 ). In Experiment 2, serum FFA concentration increased by 30% and EE decreased by 14% when the HF/HF+BM group was compared with the HF group. The magnitude of the change was similar to the 27% increase and 16% decrease in serum FFA and EE, respectively, when the HF/LF group was compared with the LF group. We contend that a high FFA concentration might be an integral part of a physiologic process that lowers metabolic efficiency.
With a few exceptions (12 ,25 ,26 ), the hypoglycemic effect of BM has been well documented. The controversial results are likely due to variations in the method of preparation (fruit with or without seeds; aqueous or organic extract) and dosing scheme (gavage or addition to the diet). In Experiment 1, the doses selected [equivalent to 5, 10 and 20 mL fruit juice/(kg body weight · d)] were based on the reported improvement in glucose tolerance when animals were given fruit juice (10 mL per kg) orally once a day for 5 d (27 ) or 10 wk (11 ,14 ). In a separate study (data not shown), however, we did not observe a hypoglycemic effect at wk 3 of BM (0.75%) supplementation. The data suggest, therefore, that different mechanisms of action might mediate the acute and chronic effects of BM on glycemia.
Over the years, several mechanisms have been put forward to explain the hypoglycemic effect of BM. For instance, a fraction that competitively inhibits intestinal glucose uptake has been identified (9 ). Others have shown that BM extracts stimulated insulin release from isolated pancreatic islet cells (28 ,29 ). The improvement in glucose tolerance, however, is independent of an increase in blood insulin (7 ,30 33 ). The presence of insulinomimetic agent(s) in BM is supported by the isolation of an 11-kDa protein (p-insulin) which is hypoglycemic when given subcutaneously to human diabetics (10 ). To the best of our knowledge, the present study is the first to demonstrate that BM improves insulin resistance (lower IRI) and reverses high fat dietinduced glucose intolerance (reduced AUCglucose). The present data, however, suggest that an insulinomimetic action, if one exists, would be minor because serum FFA concentration was increased rather than decreased. We hypothesize that the hypoglycemic effect of BM is secondary to the metabolic environment associated with reduced adiposity.
The potential involvements of leptin and TNF-
were also explored. Both hormones appear to play a role in insulin resistance (34
). A positive correlation was observed between serum insulin and leptin (Experiment 1, r = 0.72, df = 41, P < 0.01; Experiment 2, r = 0.51, df = 37, P < 0.01). Because the relationship disappeared when visceral fat mass was controlled, the metabolic effects are likely not initiated by leptin. Although TNF-
could influence leptin production (35
), no correlation between the two hormones was observed (Experiment 2: r = -0.16, P = 0.325). Nevertheless, a positive correlation between serum TNF-
and serum FFA (r = 0.34, df = 37, P < 0.01) supports a lipolytic role of TNF-
(36
).
In summary, BM alters energy balance through its effects on fat metabolism. The improved insulin resistance could be secondary to a decrease in visceral fat content. The observed effects are likely induced by more than one bioactive compound present in BM. Thus, dietary BM supplementation offers an alternate approach for studying the complex relationships among energy balance, adiposity and endocrine functions.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: AUC, area under the curve; BM, bitter melon; EE, energy efficiency; FFA, free fatty acids; HF, high fat; IRI, insulin resistance index; LF, low fat; OGTT, oral glucose tolerance test; TNF-
, tumor necrosis factor-
. ![]()
Manuscript received 28 October 2002. Initial review completed 19 November 2002. Revision accepted 19 December 2002.
| LITERATURE CITED |
|---|
|
|
|---|
1. Alberti, K.G.M.M. & Zimmet, P. Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 13:539-553.
2. Marles, R. & Farnsworth, N. R. (1995) Antidiabetic plants and their active constituents. Phytomedicine 2:137-189.
3. Li, Shizhen (1999) Ben Cao Gan Mu1578 1999 Ren Ming Wei Sheng Press Beijing, China.
4. Srivastava, Y., Venkatakrishna-Bhatt, H. & Verma, Y. (1988) Effects of Momordica charantia Linn. pomous aqueous extract on cataractogenesis in murrin alloxan diabetics. Pharmacol. Res. Commun. 20:201-209.[Medline]
5. Srivastava, Y., Venkatakrishna-Bhatt, H., Verma, Y., Venkaiah, K. & Raval, B. H. (1993) Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother. Res. 7:285-289.
6. Shibib, B. A., Khan, L. A. & Rahman, R. (1993) Hypoglycemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J. 292:267-270.
7. Akhtar, M. S., Athar, M. A. & Yaqub, M. (1981) Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits. Planta Med. 42:205-212.[Medline]
8. Leatherdale, B. A., Panesar, R. K., Singh, G., Atkins, T. W., Bailey, C. J. & Bignell, A. H. C. (1981) Improvement in glucose tolerance due to Momordica charantia (Karela). Br. Med. J. 282:1823-1824.
9. Meir, P. & Yaniv, Z. (1985) An in vitro study on the effects of Momordica charantia on glucose uptake and glucose metabolism in rats. Planta Med. 51:12-16.[Medline]
10. Khanna, P., Jain, S. C., Panagariya, A. & Dixit, V. P. (1981) Hypoglycemic activity of polypeptide-P from a plant source. J. Nat. Prod. 44:648-655.[Medline]
11. Ahmed, I., Adeghate, E., Sharma, A. K., Pallot, D. J. & Singh, J. (1998) Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res. Clin. Pract. 40:145-151.[Medline]
12. Platel, K., Shurpalekar, K. S. & Srinivasan, K. (1993) Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Die Nahrung 37:156-160.[Medline]
13. Jayasooriya, A. P., Sakono, M., Yukizaki, C., Kawano, M., Yamamoto, K. & Fukuda, N. (2000) Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J. Ethnopharmacol. 72:331-336.[Medline]
14. Ahmed, I., Lakhani, M. S., Gillett, M., John, A. & Raza, H. (2001) Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (Karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 51:155-161.[Medline]
15. American Institute of Nutrition (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76 A rodent diet. J. Nutr. 123:1939-1951.
16. Association of Official Analytical Chemists (1990) Official Methods of Analysis 15th ed. 1990 AOAC Washington, DC.
17. Koyama, K., Chen, G., Lee, Y. & Unger, R. H. (1997) Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am. J. Physiol. 273:E708-E713.
18. Ahren, B. & Scheurink, J. W. (1998) Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. Eur. J. Endocrinol. 139:461-467.[Abstract]
19. Nadkarni, A. K. (1982) 3rd ed. Indian Materia Medica 1:805-807 Popular Prakashan PVT Bombay, India.
20. Raman, A. & Lau, C. (1996) Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 2:349-362.
21. Scartezzini, P. & Speroni, E. (2000) Review on some plants of Indian traditional medicine with antioxidant activity. J. Ethnopharmacol. 71:23-43.[Medline]
22. Astrup, A & Finer, N. (2000) Redefining type 2 diabetes: diabesity or obesity dependent diabetes mellitus?. Obes. Rev. 1:57-59.[Medline]
23. Dalgaard, L. T. & Pedersen, O. (2001) Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and type II diabetes. Diabetologia 44:946-965.[Medline]
24. Harper, M. E. & Himms-Hagen, J. (2001) Mitochondrial efficiency: lessons learned from transgenic mice. Biochim. Biophys. Acta 1504:159-172.[Medline]
25. Platel, K. & Srinivasan, K. (1995) Effect of dietary intake of freeze dried bitter gourd (Momordica charantia) in streptozotocin induced diabetic rats. Nahrung 39:262-268.[Medline]
26. Karunanayake, E. H., Jeevathayaparan, S. & Tennekoon, K. H. (1990) Effect of Momordica charantia fruit juice on streptozotocin induced diabetes in rats. J. Ethnopharmacol. 30:199-204.[Medline]
27. Sitasawad, S. L., Shewade, Y. & Bhonde, R. (2000) Role of bittergourd fruit juice in STZ-induced diabetic state in vivo and in vitro. J. Ethnopharmacology 73:71-79.[Medline]
28. Welihinda, J., Gylfe, E., Karlsson, E. & Hellman, B. (1982) Effect of a hypoglycemic plant extract (Momordica charantia) on isolated pancreatic islets rich in ß-cells. Acta Endocrinol. 100:S247.
29. Ali, L., Khan, A.K.A., Mamun, M.I.R., Mosihuzzaman, M. M., Nahar, N., Nur-e-Alam, M. & Rokeya, B. (1993) Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med. 59:408-412.[Medline]
30. Day, C., Cartwright, T., Provost, J. & Bailey, C. J. (1990) Hypoglycemic effect of Momordica charantia extracts. Planta Med. 56:426-429.[Medline]
31. Sarkar, S., Pranava, M. & Marita, A. R. (1996) Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol. Res. 33:1-4.[Medline]
32. Sharma, A. K., Ahmed, I., Tadayyon, M., Ponery, A. S., Aloamaka, P., Absood, G. & Pallot, D. J. (1996) The beneficial effects of Momordica charantia fruit juice on streptozotocin induced diabetes and hypertension in rats. Int. J. Diabetes 4:29-38.
33. Vikrant, V., Grover, J. K., Tandon, N., Rathi, S. S. & Gupta, N. (2001) Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J. Ethnopharmacol. 76:139-143.[Medline]
34. Khan, B. B. & Flier, J. S. (2000) Obesity and insulin resistance. J. Clin. Investig. 106:473-481.[Medline]
35. Sethi, J. K. & Hotamisligil, G. S. (1999) The role of TNF
in adipocyte metabolism. Semin. Cell Dev. Biol. 10:19-29.[Medline]
36. Green, A., Dobias, S. B., Walters, D. J. & Brasier, A. R. (1994) Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 134:2581-2588.[Abstract]
This article has been cited by other articles:
![]() |
Y. Zhang, K. Guo, R. E. LeBlanc, D. Loh, G. J. Schwartz, and Y.-H. Yu Increasing Dietary Leucine Intake Reduces Diet-Induced Obesity and Improves Glucose and Cholesterol Metabolism in Mice via Multimechanisms Diabetes, June 1, 2007; 56(6): 1647 - 1654. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Y. Chan, Q. Chen, A. G. G. Go, E. K. Y. Lam, and E. T. S. Li Reduced Adiposity in Bitter Melon (Momordica charantia)-Fed Rats Is Associated with Increased Lipid Oxidative Enzyme Activities and Uncoupling Protein Expression J. Nutr., November 1, 2005; 135(11): 2517 - 2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V. Nerurkar, L. Pearson, J. T. Efird, K. Adeli, A. G. Theriault, and V. R. Nerurkar Microsomal Triglyceride Transfer Protein Gene Expression and ApoB Secretion Are Inhibited by Bitter Melon in HepG2 Cells J. Nutr., April 1, 2005; 135(4): 702 - 706. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||